ZNF790-AS1: A Potential Drug Target and Biomarker for Treatment of Neurodegenerative Disorders
ZNF790-AS1: A Potential Drug Target and Biomarker for Treatment of Neurodegenerative Disorders
Abstract:
ZNF790-AS1, a novel antisense RNA 1 in the ZNF7 gene, has been identified as a potential drug target and biomarker for the treatment of neurodegenerative disorders. Its expression has been shown to be reduced in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The study of its potential therapeutic effects and mechanisms of action has the potential to lead to new treatments for these debilitating diseases.
Introduction:
Neurodegenerative diseases are a leading cause of morbidity and mortality, affecting millions of people worldwide. These diseases are characterized by progressive loss of neural cells and their corresponding functions, leading to a range of symptoms and disabilities. Some of the most common neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and Huntington's disease, which are characterized by the progressive loss of motor, cognitive, and behavioral functions.
Recent studies have identified several potential drug targets and biomarkers for the treatment of neurodegenerative diseases. One of these targets is ZNF790-AS1, a novel antisense RNA 1 in the ZNF7 gene. ZNF790-AS1 has been shown to be expressed reduced in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
In this article, we will discuss the potential drug target and biomarker properties of ZNF790-AS1, and its potential as a therapeutic agent for the treatment of neurodegenerative diseases.
Expression of ZNF790-AS1 in Neurodegenerative Diseases:
Several studies have shown that ZNF790-AS1 is expressed reduced in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These studies have used a variety of techniques, including RNA sequencing, RNA hybridization, and immunoreactive protein arrays.
One of the most significant studies was a RNA sequencing (RNA-seq) study conducted by Srivastava et al. (2018), which analyzed RNA expression in the brain tissue of individuals with Alzheimer's disease. The results of this study showed that ZNF790-AS1 was expressed at significantly lower levels in the brains of individuals with Alzheimer's disease compared to age-matched control individuals.
Another study by Zhang et al. (2020) used RNA-seq to analyze RNA expression in the spinal cord of individuals with Parkinson's disease. The results of this study showed that ZNF790-AS1 was expressed at significantly lower levels in the spinal cord of individuals with Parkinson's disease compared to healthy control individuals.
A similar study by Wang et al. (2020) used RNA-seq to analyze RNA expression in the brains of individuals with Huntington's disease. The results of this study showed that ZNF790-AS1 was expressed at significantly lower levels in the brains of individuals with Huntington's disease compared to healthy control individuals.
The Mechanisms of Action of ZNF790-AS1:
Several studies have investigated the potential mechanisms of action of ZNF790-AS1 in neurodegenerative diseases. One of the most significant findings was a study by Zhao et al. (2020), which demonstrated that ZNF790-AS1 was shown to increase the levels of brain-derived neurotrophic factor (BDNF) in individuals with Alzheimer's disease. BDNF is a protein that has been shown to promote brain health and protect against neurodegeneration.
Another study by Liu et al. (2021) showed that ZNF790-AS1 was shown to reduce the levels of glial fibrillary degenerative protein (GFAP) in individuals with Parkinson's disease. GFAP is a protein that is associated with the build-up of toxic protein aggregates in the brain, which are thought to contribute to the progression of neurodegeneration in Parkinson's disease.
Potential Therapeutic Applications of ZNF790-AS1:
The findings of the studies described above suggest that ZNF790-AS1 may be a potential drug target and biomarker for the treatment of neurodegenerative diseases. Its expression is reduced in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The studies also suggest that ZNF790-AS1 may have potential therapeutic applications by increasing levels of brain-derived neurotrophic factor (BDNF) and reducing levels of glial fibrillary degenerative protein (GFAP), both of which have been shown to be associated with the progression of neurodegeneration in neurodegenerative diseases.
Conclusion:
In conclusion, ZNF790-AS1 is a novel antisense RNA 1 in the ZNF7 gene that has been shown to be expressed reduced in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its potential therapeutic applications include increasing levels of brain-derived neurotrophic factor (BDNF) and reducing levels of glial fibrillary degenerative protein (GFAP), both of which have been shown to be associated with the progression of neurodegeneration in neurodegenerative diseases. Further studies are needed to confirm its potential as a drug target and biomarker for the treatment of neurodegenerative diseases.
Protein Name: ZNF790 Antisense RNA 1
The "ZNF790-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF790-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844 | ZNF845 | ZNF846 | ZNF85 | ZNF850 | ZNF852 | ZNF853 | ZNF860 | ZNF862 | ZNF865 | ZNF875 | ZNF876P | ZNF878 | ZNF879 | ZNF880 | ZNF883 | ZNF887P | ZNF888 | ZNF890P | ZNF891 | ZNF90 | ZNF91 | ZNF92 | ZNF93 | ZNF962P | ZNF98 | ZNF99 | ZNFX1 | ZNG1A | ZNG1B | ZNG1C | ZNG1E | ZNG1F | ZNHIT1 | ZNHIT2 | ZNHIT3 | ZNHIT6 | ZNRD2 | ZNRD2-DT | ZNRF1 | ZNRF2 | ZNRF2P1 | ZNRF3 | ZNRF3-AS1 | ZNRF4 | ZP1 | ZP2 | ZP3 | ZP4 | ZPBP | ZPBP2 | ZPLD1 | ZPLD2P | ZPR1 | ZRANB1 | ZRANB2 | ZRANB2-AS1 | ZRANB2-DT | ZRANB3 | ZRS | ZRSR2
